Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to ...

Organon has acquired regulatory and commercial rights in the United States from Biogen for Tofidence, a biosimilar to Actemra for intravenous infusion. Tofidence, the first approved tocilizumab ...

Organon, a women’s health-focused pharma company based in Jersey City, expects to eliminate 93 jobs as part of an effort to optimize internal operations. In a filing with the state Department of Labor ...

Morgan Stanley lowered the firm’s price target on Organon (OGN) to $15 from $16 and keeps an Equal Weight rating on the shares. The firm ...

Organon OGN shares soared 8.5% in the last trading session to close at $12.64. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...